Abstract
Background and importanceTocilizumab is a humanised anti-interleukin-6 receptor monoclonal antibody. Intravenous tocilizumab is approved for use in children aged 2 years or older with polyarticular juvenile idiopathic arthritis (PJIA). Recently,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have